Document Detail

sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.
MedLine Citation:
PMID:  25041999     Owner:  NLM     Status:  Publisher    
Neuroblastoma (NB), the most common and deadly extracranial solid tumour of childhood, represents a challenging in paediatric oncology. Soluble tumour necrosis factor (TNF)-related apoptosis-inducing ligand (sTRAIL) is a cancer cell-specific molecule exerting remarkable anti-tumour activities against paediatric malignancies both in vitro and in preclinical settings. However, due to its too fast elimination and to the undesired related side effects, the improvement of sTRAIL in vivo bioavailability and the specific delivery to the tumour is mandatory for increasing its therapeutic efficacy. In this manuscript, we developed an innovative pegylated liposomal formulation carrying the sTRAIL at the outer surface (sTRAIL-SL) with the intent to improve its serum half-life and increase its efficacy in vivo, while reducing side effects. Furthermore, the possibility to combine sTRAIL-SL with the proteasome inhibitor Bortezomib (BTZ) was investigated, being BTZ able to sensitize tumour cells toward TRAIL-induced apoptosis. We demonstrated that sTRAIL preserved and improved its anti-tumour activity when coupled to nanocarriers. Moreover, sTRAIL-SL ameliorated its PK profile in blood allowing sTRAIL to exert a more potent anti-tumour activity, which led, upon BTZ priming, to a statistically significant enhanced life spans in two models of sTRAIL-resistant NB-bearing mice. Finally, mechanistic studies indicated that the combination of sTRAIL with BTZ sensitized sTRAIL-resistant NB tumour cells to sTRAIL-induced cell death, both in vitro and in vivo, through the Akt/GSK3/β-catenin axis-dependent mechanism. In conclusion, our results suggest that sTRAIL-SL might be an efficient vehicle for sTRAIL delivery and that its use in clinic, in combination with BTZ, might represent an adjuvant strategy for the treatment of stage IV, sTRAIL-resistant, NB patients.
M Loi; P Becherini; L Emionite; A Giacomini; I Cossu; E Destefanis; C Brignole; D Di Paolo; F Piaggio; P Perri; M Cilli; F Pastorino; M Ponzoni
Related Documents :
17166399 - Effect of bifidobacterium infantis on interferon- gamma- induced keratinocyte apoptosis...
19404869 - Mercury modulates interplay between il-1beta, tnf-alpha, and gap junctional intercellul...
19357709 - The role of leukocytes, keratinocytes, and allergen-specific ige in the development of ...
20642779 - A novel mechanism of cutaneous photo-aging mediated by the impairment of lymphatic func...
19601979 - Effector pathways during eczematous dermatitis: where inflammation meets cell death.
16936269 - B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse m...
12487809 - Differences in cellular activation and apoptosis in hiv-infected patients receiving pro...
24535699 - Effect of transforming growth factor-β1 on acute lung injury caused by paraquat.
19399019 - Anca-negative pauci-immune crescentic glomerulonephritis.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-7-17
Journal Detail:
Title:  Journal of controlled release : official journal of the Controlled Release Society     Volume:  -     ISSN:  1873-4995     ISO Abbreviation:  J Control Release     Publication Date:  2014 Jul 
Date Detail:
Created Date:  2014-7-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8607908     Medline TA:  J Control Release     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014. Published by Elsevier B.V.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Suppression in mice of immunosurveillance against PEGylated liposomes by encapsulated doxorubicin.
Next Document:  Electrospun Tecophilic/gelatin nanofibers with potential for small diameter blood vessel tissue engi...